SE:RO Roche Holding AG

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses worldwide. The company offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. It also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; anti-platelet therapy monitoring; neonatal intensive care; nucleic acid purification; PCR clinical diagnostics and real-time PCR diagnostic systems; pharmacogenomics; physical fitness and platelet function testing; serum work area; urinalysis; and workflow solutions. In addition, the company offers cell analysis, gene expression, genome sequencing, nucleic acid purification, and real-time PCR systems for researchers. Roche Holding AG has a clinical collaboration agreement with Epizyme, Inc. to study tazemetostat administered in combination with atezolizumab for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer. The company was founded in 1896 and is headquartered in Basel, Switzerland.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol RHHBF.

This company has cross-listed shares that trade in the U.S. as the symbol RHHBF.

370.60 CHF
As of 07/05/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-General
Index country:  Switzerland
Country of incorporation:  Switzerland
IPO date:  01/04/2000
Stock exchange:    Six Swiss Exchange
Exchange country:   Switzerland
Market cap:   281,087,639,552 CHF
Current dividend yield:   2.62%
Sedol:      7108918

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy